Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Dec 13:14:05027.
doi: 10.7189/jogh.14.05027.

Hypertonic saline nasal irrigation and gargling for suspected or confirmed COVID-19: Pragmatic randomised controlled trial (ELVIS COVID-19)

Affiliations
Randomized Controlled Trial

Hypertonic saline nasal irrigation and gargling for suspected or confirmed COVID-19: Pragmatic randomised controlled trial (ELVIS COVID-19)

Osman M Yusuf et al. J Glob Health. .

Abstract

Background: In a previous pilot randomised controlled trial conducted on UK adults, we found that hypertonic saline nasal irrigation and gargling (HSNIG) reduced common cold symptoms, the need for over-the-counter medications, viral shedding, and the duration and transmission of the illness. It is unclear whether HSNIG improves outcomes of the coronavirus disease 2019 (COVID-19). Hypertonic saline can be prepared and HSNIG performed at home, making it a safe and scalable intervention, particularly well-suited for low- and middle-income countries.

Methods: We conducted a pragmatic randomised controlled trial in Pakistan on adults with suspected or confirmed COVID-19, initially within 48 hours of symptom onset, later extended to within five days due to recruitment challenges. Participants were randomised to one of two groups: the intervention group received instructions on preparing a 2.6% hypertonic saline solution for HSNIG, while the control group was instructed on performing ablution for Muslim prayers (wudu), which involves nasal washing and gargling with tap water. Our primary outcome was the time to symptom resolution, measured by two consecutive days of scoring zero on relevant questions from the validated, self-reported, adapted short form of the Wisconsin Upper Respiratory Symptom Survey (WURSS-24). Secondary outcomes included the severity of all symptoms, the severity and time to resolution of individual symptoms, health care contacts (GP/physician, emergency contacts), hospital attendance (and length of stay if admitted), over-the-counter (OTC) medication (frequency and cost), and transmission to household contacts. The analysis was conducted on an intention-to-treat basis. Logistic regression was used to calculate adjusted odds ratios (aORs) of improvement and Cox regression to calculate adjusted hazard ratios (aHRs) for the time to improvement with accompanying 95% confidence intervals (CIs).

Results: We randomised 576 people: 279 to the HSNIG group and 297 to the control group. Among those, 10 out of 279 (3.6%) in the HSNIG had symptom resolution, compared with 11 out of 297 (3.7%) in the control group (aOR = 1.20, 95% CI = 0.46- 3.22). The time-to-event analysis also showed no significant benefit (aHR = 1.23, 95% CI = 0.51-2.97). Excluding the 127 participants with no data on the primary outcome (who did not complete the study), 10 out of 222 (4.5%) in the HSNIG group had symptom resolution, compared to 11 out of 227 (4.8%) in the control group.

Conclusions: HSNIG was not effective for individuals with suspected or confirmed COVID-19 who began the intervention within five days of symptoms onset and therefore cannot be recommended for use. Further investigation is needed for interventions started within 48 hours of illness onset.

Registration: ClinicalTrials.gov (NCT05104372).

PubMed Disclaimer

Conflict of interest statement

Disclosure of interest: The authors completed the ICMJE Disclosure of Interest Form (available upon request from the corresponding author) and disclose the following activities and/or relationships: AS was a member of the Scottish Government Chief Medical Officer’s COVID-19 Advisory Group and is a member of its Standing Committee on Pandemics. He was also a member of the UK Government’s New and Emerging Virus Threats Advisory Group (NERVTAG) Risk Stratification Subgroup. All roles are unremunerated. All other authors report no relevant conflicts of interest.

Figures

Figure 1
Figure 1
CONSORT flow diagram.
Figure 2
Figure 2
Primary outcome – score on ‘How sick today? (0–7)’ across time. Black solid line shows the active group (intervention, with dotted black lines representing lower and upper 95% confidence bands. The red solid line shows the standard group (control), with dotted red lines denoting the lower and upper 95% confidence bands.
Figure 3
Figure 3
Average number of times nasal irrigation and gargling was performed daily. A black solid line shows the active group (intervention, with dotted black lines representing lower and upper 95% confidence bands. The red solid line shows the standard group (control), with dotted red lines denoting the lower and upper 95% confidence bands.
Figure 4
Figure 4
Kaplan-Meier Time to achieving two consecutive days zero score on ‘How sick do you feel’ (primary outcome). The red solid line shows the active group (intervention), while the red lines show the lower and upper 95% confidence bands. The blue solid line shows the standard group (control), with dotted blue lines showing the corresponding lower and upper 95% confidence bands. The x-axis shows the time in days in days.

References

    1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382:727–33. 10.1056/NEJMoa2001017 - DOI - PMC - PubMed
    1. Worldometer. Coronavirus. 2024. Available: https://www.worldometers.info/coronavirus/. Accessed: 4 January 2024.
    1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536–44. 10.1038/s41564-020-0695-z - DOI - PMC - PubMed
    1. Geng Y, Wang Y.Stability and transmissibility of SARS-CoV-2 in the environment. J Med Virol. 2023;95:e28103. 10.1002/jmv.28103 - DOI - PMC - PubMed
    1. Sheikh A, McMenamin J, Taylor B, Robertson C.Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397:2461–2. 10.1016/S0140-6736(21)01358-1 - DOI - PMC - PubMed

Publication types

Substances

Associated data